Remove Blogging Remove Capital Remove San Diego Remove UCSD
article thumbnail

With $20M, UCSD Spinout Jecure To Press New Attack On NASH

Xconomy

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64
article thumbnail

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Xconomy

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years.

San Diego 121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch

Xconomy

Founders Jared Tagney and Joshua Windmiller, who met while in grad school at UC San Diego, started the company in 2012 as Electrozyme. The San Diego startup. The company began focusing on the technology it is currently developing in 2015, Tagney said. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 103
article thumbnail

LabFellows Looks to Become “Operating System” For Life Sciences Cos.

Xconomy

However, that wasn’t the problem San Diego startup LabFellows was looking to solve when it launched in 2014. Scientists, no matter how sexy the research they’re conducting, aren’t immune from the administrative minutiae of office life. Such tasks steal time away from researchers’ main objectives.

San Diego 112
article thumbnail

BioIntervene Raises $30M to Move Nerve Pain Drug Into the Clinic

Xconomy

Now the San Diego-based biotech has $30 million and a chief scientific officer, Charles Cohen, to guide its lead compound, BIO-205, into human testing for neuropathic pain. The company announced the Series A financing round and CSO hire on Monday.